ASIRI HOSPITAL HOLDINGS PLC

PROVISIONAL ACCOUNTS FOR THE PERIOD ENDED
30th June 2026

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF PROFIT OR LOSS

For the Period Ended 30 June 2026

	GROUP		COMPANY	
	30-Jun-26	**30-Jun-25**	**30-Jun-26**	**30-Jun-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Revenue	**9,516,040,786**	8,720,270,632	**4,242,254,188**	3,933,940,125
Cost of Services	**(4,666,375,484)**	(4,281,622,981)	**(1,920,273,186)**	(1,817,402,186)
Gross Profit	**4,849,665,302**	4,438,647,651	**2,321,981,002**	2,116,537,939
Other Income	**72,343,894**	76,227,194	**43,718,671**	43,728,494
Administrative Expenses	**(2,681,175,826)**	(2,246,304,828)	**(1,049,907,585)**	(908,932,763)
Selling and Distribution Expenses	**(308,996,819)**	(232,653,395)	**(146,194,358)**	(125,091,197)
Finance Costs	**(499,260,137)**	(492,630,353)	**(453,809,914)**	(385,558,242)
Finance Income	**466,132,004**	206,520,821	**197,388,943**	55,629,059
Profit Before Tax	**1,898,708,418**	1,749,807,090	**913,176,758**	796,313,289
Tax Expense	**(536,504,589)**	(523,500,379)	**(230,864,261)**	(230,126,988)
Profit for the Period	**1,362,203,829**	1,226,306,711	**682,312,497**	566,186,301
Attributable to:				
Equity Holders of the Parent Company	**1,284,617,898**	1,158,335,105		
Non-Controlling Interest	**77,585,931**	67,971,606		
	1,362,203,829	1,226,306,711		
Earnings Per Share- Basic	**1.13**	1.02	**0.60**	0.50
Dividend Per Share- Ordinary Shares	**0.00**	**0.00**	**0.00**	**0.00**

STATEMENT OF COMPREHENSIVE INCOME

For the Period Ended 30 June 2026

	Group		Company	
	30-Jun-26	**30-Jun-25**	**30-Jun-26**	**30-Jun-25**
	Rs.	**Rs.**	**Rs.**	**Rs.**
	Un-audited	**Un-audited**	**Un-audited**	**Un-audited**
Profit for the Period	**1,362,203,829**	1,226,306,711	**682,312,497**	566,186,301
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net change in fair value of equity instruments designated at FVOCI	-	-	(191,645,947)	-
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods:	-	-	**(191,645,947)**	-
Other Comprehensive Income to be reclassified to Statement of Profit or Loss in subsequent periods:				
Net Other Comprehensive Income to be reclassified to Statement of Profit or Loss in subsequent periods	-	-	-	-
Other Comprehensive Income/(Loss) for the Period, Net of Tax	-	-	**(191,645,947)**	-
Total Comprehensive Income/(Loss) for the Period, Net of Tax	**1,362,203,829**	1,226,306,711	**490,666,550**	566,186,301
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent Company	**1,284,617,898**	1,158,335,105		
Non-Controlling Interest	**77,585,931**	67,971,606		
	1,362,203,829	1,226,306,711		

Asiri Hospital Holdings PLC and Its Subsidiaries

STATEMENT OF FINANCIAL POSITION

GROUP 31-Mar-26 Rs. Un-audited	COMPANY 31-Mar-26 Rs. Un-audited		GROUP 30-Jun-26 Rs. Un-audited	GROUP 30-Jun-25 Rs. Un-audited	COMPANY 30-Jun-26 Rs. Un-audited	COMPANY 30-Jun-25 Rs. Un-audited
		ASSETS				
		Non-current Assets				
34,785,399,678	14,512,372,089	Property, Plant and Equipment	**34,900,982,321**	33,428,429,809	**14,485,414,889**	14,050,528,384
1,377,036,756	1,047,467,378	Right of Use Assets	**1,362,098,925**	1,250,568,428	**1,031,018,877**	943,260,696
609,654,071		Goodwill	**609,654,071**	609,654,071	**-**	-
-	41,413,818,295	Investment in Subsidiaries	-	-	**40,869,303,077**	12,345,794,784
5,108,760,171		Loans granted to Related Parties	**5,108,760,172**	5,108,760,172	**-**	-
83,146,859	57,164,859	Other Non Current Assets	**76,655,693**	72,225,096	**50,673,693**	46,243,096
57,200,837	57,200,837	Other Non-Current Financial Assets	**1,061,433,502**	30,000,000	**1,061,433,502**	30,000,000
42,021,198,372	**57,088,023,459**		**43,119,584,685**	40,499,637,577	**57,497,844,038**	27,415,826,960
		Current Assets				
1,361,112,081	612,660,847	Inventories	**1,415,045,146**	1,058,197,109	**604,318,101**	484,957,405
1,893,812,366	3,028,082,999	Trade and Other Receivables	**2,444,284,141**	2,432,754,457	**4,596,045,446**	2,924,874,683
5,720,974,477	3,185,416,849	Loans Granted to Related Parties	**5,959,992,415**	7,536,698,802	**3,263,651,475**	1,716,473,380
8,110,590,168	4,017,039,179	Other Current Assets	**9,544,973,747**	7,052,569,847	**3,980,875,092**	796,786,043
919,290,575	120,653,845	Cash and Cash Equivalents	**1,036,462,345**	920,309,885	**137,983,215**	175,455,181
18,005,779,667	**10,963,853,719**		**20,400,757,794**	19,000,530,100	**12,582,873,329**	6,098,546,692
60,026,978,039	**68,051,877,178**	**Total Assets**	**63,520,342,482**	59,500,167,677	**70,080,717,367**	33,514,373,652
		EQUITY AND LIABILITIES				
		Capital and Reserves				
4,748,108,334	4,748,108,334	Stated Capital	**4,748,108,334**	4,748,108,334	**4,748,108,334**	4,748,108,334
10,789,318,283	27,625,138,125	Other Components of Equity	**10,845,232,804**	10,593,398,333	**27,207,685,973**	3,943,767,585
8,605,743,762	3,866,307,089	Retained Earnings	**9,890,361,660**	8,600,717,958	**4,774,425,791**	2,584,994,993
24,143,170,379	**36,239,553,548**	**Share Holders' Fund**	**25,483,702,798**	23,942,224,625	**36,730,220,098**	11,276,870,912
2,049,314,730	-	Non-Controlling Interests	**2,423,855,276**	2,005,321,612	-	-
26,192,485,110	**36,239,553,548**	**Total Equity**	**27,907,558,075**	25,947,546,237	**36,730,220,098**	11,276,870,912
		Non-current Liabilities				
5,507,958,130	8,241,630,884	Interest Bearing Loans and Borrowings	**5,455,715,826**	5,199,578,934	**8,124,432,837**	7,570,909,073
5,525,705,285	8,642,983,872	Deferred Tax Liabilities	**5,614,029,817**	5,376,183,728	**8,738,509,548**	2,638,070,308
1,127,247,507	451,918,687	Employee Benefit Liability	**1,160,972,151**	862,007,043	**463,749,265**	350,114,478
12,160,910,921	**17,336,533,444**		**12,230,717,794**	11,437,769,705	**17,326,691,650**	10,559,093,859
		Current Liabilities				
6,016,220,984	3,953,122,648	Trade and Other Payables	**6,696,016,144**	6,637,707,423	**4,225,499,243**	1,821,635,269
92,001,206	77,691,781	Dividend Payable	**92,001,206**	93,458,428	**77,691,781**	78,566,589
8,390,145,360	6,696,582,567	Interest Bearing Loans and Borrowings	**9,296,465,089**	9,322,732,731	**7,766,504,131**	6,979,680,289
3,000,244,624	1,268,101,329	Income Tax Payable	**3,213,359,005**	1,706,679,439	**1,336,239,914**	343,445,516
4,174,969,835	2,480,291,859	Bank Overdraft	**4,084,225,169**	4,354,273,715	**2,617,870,550**	2,455,081,219
21,673,582,009	**14,475,790,186**		**23,382,066,612**	22,114,851,736	**16,023,805,620**	11,678,408,882
60,026,978,039	**68,051,877,178**	**Total Equity and Liabilities**	**63,520,342,482**	59,500,167,677	**70,080,717,367**	33,514,373,652
21.22	31.86	Net Assets Per Share	22.40	21.05	32.29	9.91

The above figures are provisional & subject to audit.
It is certified that the Financial Statements have been prepared in accordance with the requirements of the Companies Act No.7 of 2007.

-sgd-
.....
S L R Piyal
Director Finance

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.
Signed for and on behalf of the Board.

-sgd-
.....
Ashok Pathirage
Chairman / Managing Director

-sgd-
.....
Haresh Kaimal
Director

05 August 2026
Colombo

STATEMENT OF CHANGES IN EQUITY
For the Period Ended 30 June 2026

GROUP

	Equity Attributable to Equity Holders of the Parent							
	Stated Capital	Revaluation Reserve	Reserve on Consolidation	Retained Earnings	Fair Value Reserve of Financial Assets at FVOCI	Foreign Currency Translation Reserve	Minority Interest	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 01 April 2025	**4,748,108,334**	**10,592,574,929**	**(919,386,922)**	**8,361,769,775**	**-**	**823,404**	**1,937,350,006**	**24,721,239,526**
Profit for the Period	-	-	-	1,158,335,105	-	-	67,971,606	1,226,306,711
Other Comprehensive Income	-	-	-		-	-	-	-
Total Comprehensive Income	**-**	**-**	**-**	**1,158,335,105**	**-**	**-**	**67,971,606**	**1,226,306,711**
Acquisition of Non- controlling interests	-	-	-	-	-	-	-	-
Balance as at 30 June 2025	**4,748,108,334**	**10,592,574,929**	**(919,386,922)**	**9,520,104,880**	**-**	**823,404**	**2,005,321,612**	**25,947,546,237**
Balance as at 01 April 2026	**4,748,108,334**	**11,693,431,117**	**(919,502,000)**	**8,605,743,762**	**19,040,586**	**(3,651,420)**	**2,049,314,730**	**26,192,485,110**
Profit for the Period	-	-	-	1,284,617,898	-	-	77,585,931	1,362,203,829
Other Comprehensive Income	-	-	-	-	-	-	-	-
Total Comprehensive Income	**-**	**-**	**-**	**1,284,617,898**	**-**	**-**	**77,585,931**	**1,362,203,829**
Acquisition of Non- controlling interests	-	-	-	-	-	-	-	-
Balance as at 30 June 2026	**4,748,108,334**	**11,693,431,117**	**(863,587,478)**	**9,890,361,660**	**19,040,586**	**(3,651,420)**	**2,423,855,276**	**27,907,558,075**

COMPANY

	Stated Capital	Revaluation Reserve	Fair Value Reserve of Financial Assets at FVOCI	Retained Earnings	Total
	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 01 April 2025	**4,748,108,334**	**3,943,767,585**		**2,018,808,692**	**10,710,684,611**
Profit for the Period	-	-	-	566,186,301	566,186,301
Other Comprehensive Income	-				-
Total Comprehensive Income	-	-	-	566,186,301	566,186,301
Balance as at 30 June 2025	**4,748,108,334**	**3,943,767,585**	**-**	**2,584,994,993**	**11,276,870,912**
Balance as at 01 April 2026	**4,748,108,334**	**4,502,387,362**	**23,122,750,763**	**3,866,307,089**	**36,239,553,548**
Profit for the Period	-	-	-	682,312,497	682,312,497
Other Comprehensive Income	-	-	(417,452,152)	225,806,205	(191,645,947)
Total Comprehensive Income	-	-	(417,452,152)	908,118,702	490,666,550
Balance as at 30 June 2026	**4,748,108,334**	**4,502,387,362**	**22,705,298,611**	**4,774,425,791**	**36,730,220,098**

STATEMENT OF CASH FLOWS

For the Period Ended 30 June 2026

	GROUP		COMPANY	
	30-Jun-26 Rs. Un-audited	30-Jun-25 Rs. Un-audited	30-Jun-26 Rs. Un-audited	30-Jun-25 Rs. Un-audited
Cash Flows from/(used in) Operating Activities				
Profit Before Tax Expense	**1,898,708,418**	1,749,807,090	**913,176,758**	796,313,289
Adjustments for				
Depreciation	**481,183,446**	460,556,492	**203,951,327**	190,190,421
Amortization of Leasehold Assets	**63,915,923**	51,215,878	**37,625,530**	33,682,465
Loss/(Profit) on Disposal of Property, Plant and Equipment	**(51,000)**	-	**-**	-
Provision for Bad and Doubtful Debts	**27,439,425**	8,024,297	**3,478,329**	3,401,519
Provision for Retirement Gratuity	**59,798,489**	54,591,711	**23,830,370**	21,916,839
Unrealized Foreign Currency Exchange Gain	**(1,109,244)**	(3,849,287)	**(86,886)**	(3,988)
Finance Costs	**499,260,137**	492,630,353	**453,809,914**	385,558,242
Income from Investments	**(466,132,004)**	(206,520,821)	**(197,388,943)**	(55,629,059)
Operating Profit Before Working Capital Changes	**2,563,013,589**	2,606,455,713	**1,438,396,400**	1,375,429,729
Changes in Working Capital				
(Increase)/Decrease in Inventories	**(53,933,065)**	(38,683,600)	**8,342,746**	(19,986,271)
(Increase)/ Decrease in Other Current Assets	**(1,241,526,039)**	(2,612,277,731)	**136,736,891**	(123,786,555)
(Increase)/ Decrease in Trade and Other Receivables	**(523,032,349)**	(263,894,839)	**(1,571,440,776)**	(166,736,574)
(Decrease)/Increase in Trade and Other Payables	**679,795,159**	1,970,935,635	**272,376,588**	113,698,233
Cash Generated from Operations	**1,424,317,295**	1,662,535,177	**284,411,849**	1,178,618,561
Income Tax paid	**(234,354,936)**	(155,255,928)	**(67,200,000)**	(10,000,000)
Finance Costs paid	**(354,196,107)**	(385,015,676)	**(191,252,757)**	(208,692,771)
Defined Benefit Plan Costs paid	**(26,073,844)**	(60,074,694)	**(11,999,793)**	(32,871,488)
Net Cash from Operating Activities	**809,692,407**	1,062,188,879	**13,959,299**	927,054,302
Cash Flows from/(used in) Investing Activities				
Acquisition of Property, Plant and Equipment	**(597,223,422)**	(157,706,961)	**(177,090,388)**	(67,212,740)
Acquisition of Right of use assets	**(143,707)**	-	**(143,707)**	-
Increase/decrease in Interest in Subsidiaries	**352,869,137**	-	**352,869,137**	-
Increase in investment in shares	**(1,004,232,665)**	-	**(1,004,232,665)**	-
Proceed from/(repayment of) Loans Obtained From Related Parties	**(61,068,347)**	50,000,000	**-**	-
Proceeds from Disposal of Property, Plant and Equipment	**199,954**	-	**-**	-
Income From Investments	**22,508,388**	977,985	**21,847,628**	181,580
Net Cash used in Investing Activities	**(1,287,090,661)**	(106,728,976)	**(806,749,995)**	(67,031,160)
Cash Flows from/(used in) Financing Activities				
Reversal of Unclaimed Dividends	**-**	17,204,396	**-**	17,204,396
Net Proceeds/(Net Repayments) from External Borrowings	**757,527,609**	(726,235,989)	**722,593,078**	(335,529,607)
Repayment of Lease Obligations	**(72,212,922)**	(70,116,197)	**(50,051,704)**	(43,181,631)
Net Cash from/(used in) Financing Activities	**685,314,688**	(779,147,790)	**672,541,374**	(361,506,843)
Net Increase/(Decrease) in Cash and Cash Equivalents	**207,916,434**	176,312,112	**(120,249,322)**	498,516,299
Cash and Cash Equivalents at the Beginning of the Year	**(3,255,679,260)**	(3,610,275,943)	**(2,359,638,014)**	(2,778,142,338)
Cash and Cash Equivalents at the End of the Year	**(3,047,762,826)**	(3,433,963,830)	**(2,479,887,335)**	(2,279,626,038)
Analysis of Cash and Cash Equivalents				
Favorable Balances				
Cash in Hand and at Bank	**1,036,462,345**	920,309,885	**137,983,215**	175,455,181
Unfavorable Balances				
Bank Overdrafts	**(4,084,225,169)**	(4,354,273,715)	**(2,617,870,550)**	(2,455,081,219)
Cash and Cash Equivalents	**(3,047,762,826)**	(3,433,963,830)	**(2,479,887,335)**	(2,279,626,038)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 30 June 2026

1. Corporate Information

1.1 General

Asiri Hospital Holdings PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 181, Kirula Road, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the period ended 30 June 2026 were authorised for issue by the Board of Directors on 05 August 2026.

2. Basis of Preparation

The Interim Condensed Financial Statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2025 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

Group

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd ,Softlogic Super market (Pvt) Ltd, Softlogic Retail (Pvt) Ltd, ODEL PLC, Softlogic Communication Services (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

Company

This includes loans granted to Softlogic Holdings PLC, Softlogic Brands (Pvt) Ltd, ODEL PLC and Softlogic Super Market (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments from 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during that period. The Company has filed appeals against these assessments in the Court of Appeal and the cases are on going

We also have filed an appeal in the Supreme Court(vide Supreme Court Special Leave To APPEAL APP: SC/SPL/LA 69/2026] against the Judgment of the Court of Appeal dated 19th January 2026 relating to the Writ application (CA (Writ) 386/ 2016 which was filed by the Company to prevent seizure of bank accounts of the Company as part of IRD's recovery actions .

Since there are litigations, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2025.

4.3 Capital Expenditure Commitments

There were no material commitments outstanding as at 30 June 2026 for future capital expenditure except for below;
Rs.21,901,554 contracted with suppliers for the construction of Asiri Hospital Kandy (Rs.21,901,554 as at 30 June 2025).

4.4 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Events Occurring After the Reporting Period

There were no material events that occurred after the reporting date that require adjustments or disclosure to the Financial Statements.

NOTES TO THE INTERIM FINANCIAL STATEMENTS
For the Period Ended 30 June 2026

5. Segment Information

The Senior Management Committee acts as the Chief Operating Decision Maker (CODM) and reviews the operating results of the Group's business units separately to support decisions on resource allocation and performance evaluation. Segment performance is assessed based on revenue and other income generated, measured on a basis consistent with the amounts reported in the Consolidated Financial Statements.

Based on the information presented to the CODM for these purposes, the Group has identified its reportable segments accordingly for the interim period.

- Pre Care which include OPD revenue, channeling revenue and OPD lab investigation services
- Post Care which include all IPD revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes Pharmacy revenue
- Other revenue includes income generated from healthcare professional services provided by Asiri Academy of Health Sciences (Pvt) Ltd.

Segment	Group		Company	
	30-Jun-26	30-Jun-25	30-Jun-26	30-Jun-25
	Rs.	Rs.	Rs.	Rs.
	Un-audited	Un-audited	Un-audited	Un-audited
Pre Care	4,378,860,179	3,993,389,822	2,607,716,290	2,330,861,865
Post Care	4,458,317,112	4,134,854,610	1,402,891,487	1,382,408,899
Pharmaceutical	659,058,995	575,669,900	231,646,411	220,669,361
Other services	19,804,500	16,356,300		
	9,516,040,786	8,720,270,632	4,242,254,188	3,933,940,125

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Hospital Holdings PLC is as follows:

	Quarter to 30-Jun-26	Quarter to 30-Jun-25
Highest Price per Share (Rs.)	47.00	35.00
Lowest Price per Share (Rs.)	29.80	25.10
Last Traded Price per Share (Rs.)	37.80	31.90

No of Shares Representing Stated Capital	As at 30-Jun-26	As at 30-Jun-25
No of Ordinary Shares	1,137,533,596	1,137,533,596

* Earnings and net assets per share are based on 1,137,533,596 shares in issue as at 30 June 2026.

Statement of Shareholding of Directors Name of Director	As at 30-Jun-26	As at 30-Jun-25
Mr. A. K. Pathirage	371,664	371,664
Mr. Rajaratnam Selvaskadan	-	-
Mr. Vishal Bali	-	-
Mr. A. N. Thadani	-	-
Mr. H K Kaimal	-	-
Mr. Govinda Waduge Don Hemantha Udaya Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. M.I. Furkan	-	-
Mr. Galle Dodanduwage Kalum Lakmal De Silva	-	-

Major Shareholdings Twenty Largest Shareholders	As at 30-Jun-26	%	As at 30-Jun-25	%
Softlogic Holdings PLC	627,025,050	55.12	627,025,050	55.12
Merrill Lynch Pierce Fenner & Smith-Tpg Growth Iii Sf Pte Ltd	328,258,328	28.86	328,258,328	28.86
BBH-Tundra Sustainable Frontier Fund	30,000,000	2.64	30,000,000	2.64
Softlogic Life Insurance PLC-A/C No. 04 (Participating Fund)	9,000,000	0.79	9,000,000	0.79
Sri Lanka Insurance Corporation Ltd-Life Fund	7,851,792	0.69	7,851,792	0.69
Mr. Pujitha Punsiri Subasinghe	7,420,340	0.65	7,416,922	0.65
Softlogic Life Insurance PLC-A/C No. 05 (Non-Participating Fund)	5,956,877	0.52	5,956,877	0.52
Deutsche Bank Ag As Trustee For Jb Vantage Value Equity Fund	3,727,605	0.33	5,086,406	0.45
Dr.Welagedara Mudiyanselage Swarnamali Welagedara	3,375,000	0.30	3,375,000	0.30
J.B. Cocoshell (Pvt) Ltd	2,955,684	0.26	7,488,264	0.66
Mr. Hewa Komanage Jayantha Dharmadasa	2,826,650	0.25	2,908,650	0.26
Dr. Luhubanduwaduge Don Abo Claudius Luvis	2,557,423	0.22	2,741,720	0.24
Employees Trust Fund Board	2,337,161	0.21	4,245,693	0.37
Mr.Mohamed Faizer Hashim	2,087,160	0.18	2,087,160	0.18
Miss.Theja Thushari Weerasinghe	1,746,630	0.15	1,746,630	0.15
Jafferjee Brothers Exports (Private)Limited	1,616,000	0.14	3,487,500	0.31
Sri Lanka Insurance Corporation Ltd-General Fund	1,557,417	0.14	2,807,417	0.25
Mr.Vigneswaramoorthy Sunilgavasker	1,511,460	0.13	1,460	0.00
Mr.Uditha Harilal Palihakkara	1,496,857	0.13	1,431,755	0.13
Commercial Bank of Ceylon PLC/ H.G. Balasuriya	1,400,000	0.12	-	0.00
	1,044,707,434	91.84	1,052,916,624	92.56
Shares held by the Balance Shareholdings	92,826,162	8.16	84,616,972	7.44
Total Issued Shares	1,137,533,596	100.00	1,137,533,596	100.00
Public Shareholding	166,921,677	14.67	166,921,677	14.67
Total Number of Public Shareholders	6,773		5,677	

The Float- adjusted market capitalization as at 30th June 2026 is Rs.6,307,919,548.55 and the Company is in compliance with option 3 of the CSE Listing Rules 7.13.1 (i) (a) which requires 7.5 % minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Hospital Holdings PLC

Registered Office
181, Kirula Road, Colombo 05,
Sri Lanka.

Office & Administrative Complex
Asiri Surgical Hospital PLC
21, Kirimandala Mawatha,
Colombo 05, Sri Lanka.
Telephone: 011 4524400
Email: info@asiri.lk
Web: www.asirihealth.com

Company Registration Number
PQ204

Legal Form
A quoted public company incorporated in Sri Lanka on 29 September 1980, under the Companies Act No.17 of 1982, with limited liability.Re-registered on 30 September 2008 under the Companies Act No. 07 of 2007.

Stock Exchange Listing
The Ordinary Shares of the Company have been listed with the Colombo Stock Exchange since June 1986.

Board of Directors
Mr. A. K. Pathirage - Chairman/Managing Director
Mr. G. W.D.H. U. Gunawardena
Mr. Rajaratnam Selvaskandan
Mr. H K Kaimal
Mr.V. Bali
Mr. A. N. Thadani
Mr. S. Shapira
Mr. M.I. Furkan
Mr. G.D.K.L.De Silva

Audit Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Nomination and Governance Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr.V. Bali
Independent Non-Executive Director

Frequency of Meetings
Committee meets once each year or as required.

Related Party Transactions Review Committee
Chairman
Mr. M.I. Furkan
Independent Non- Executive Director

Committee Members
Mr. G.D.K.L.De Silva
Independent Non-Executive Director

Mr. H K Kaimal
Non Independent Non-Executive Director

Frequency of Meetings
Committee meets quarterly

Subsidiary Companies
Central Hospital Ltd
114, Norris Canal Road, Colombo 10.

Asiri Central Hospitals Ltd
114, Norris Canal Road, Colombo 10.

Asiri Surgical Hospital PLC
21, Kirimandala Mawatha, Colombo 5.

Asiri Diagnostics Services (Pvt) Ltd
181, Kirula Road, Colombo 05.

Asiri Hospital Matara (Pvt) Ltd
26, Esplanade Road, Uyanwatte,
Matara.

Asiri Laboratories (Pvt) Ltd
181, Kirula Road, Colombo 5.

Asiri Hospital Galle (Pvt) Ltd
10, Wackwella Road, Galle.

Asiri AOI Cancer Centre (Pvt) Ltd
21, Kirimandala Mawatha, Colombo 5.

Asiri Port City Hospital (Pvt) Ltd.
14, De Fonseka Place, Colombo 5.

Asiri Academy of Health Sciences (Pvt) Ltd.
181, Kirula Road, Colombo 5.

Asiri Diagnostics Services (Asia) Pte Limited
8, Temasek Boulevard, # 35-03 Suntec Tower 3.
Singapore.

Auditors
Messrs. Ernst & Young
(Chartered Accountants)
109, Galle Road,
Colombo 03.

Secretaries
Messrs. Softlogic Corporate Services (Pvt) Ltd
14, De Fonseka Place, Colombo 5.

Stock Code
ASIR.N0000

Bankers
Commercial Bank of Ceylon PLC
Sampath Bank PLC
Nations Trust Bank PLC
Hatton National Bank PLC
Cargills Bank Limited
Bank of Ceylon PLC
National Development Bank PLC
Seylan Bank PLC
DFCC Bank PLC
Union Bank of Colombo PLC